Background and Aims: Transrectal ultrasonography (TRUS) has proven useful for locoregional staging of rectal carcinoma in specialised centres, but the investigation is not widely used. The aim of this study was to audit the introduction of TRUS performed by surgeons without previous experience with ultrasonography.
INTRODUCTION
Precise evaluation of tumour level and extent of tumour spread is essential for planning of optimal therapy in patients with rectal cancer. The tumour stage has great influence on the resectability of the tumour and the risk of recurrence following resection.
After introduction of new surgical techniques, there is growing evidence that therapy should be individualised. Surgery alone is the optimal treatment for some subgroups of patients, whereas other subgroups may benefit from preoperative radio-and/ or chemotherapy (1-3). Ongoing studies will help to define these subgroups (4). Reliable methods for preoperative staging and expertise in these methods in institutions treating rectal cancer patients are then necessary.
Several studies the last twenty years have shown that TRUS is a valuable method for staging (5), but still, the examination is not widely used. The presented results often come from specialised centres and endoscopists or radiologists perform the investigation. The aim of this study was to audit the introduction of TRUS in a surgical department, the examination being performed on a non-selected patient material. Few rectal cancer patients receive preoperative radiotherapy in our department, and the results of TRUS could therefore be compared with the histopathological examinations of nonirrradiated resection specimens in the majority of patients.
MATERIAL AND METHODS
All patients admitted in the period 1996-2002 with rectal adenocarcinoma located within 15 cm from the anal verge, who might be candidates for curative surgery, were included in the study. A total of 118 patients, 73 (62 %) men and 45 women, were included.
The exact level above the anal verge and the longitudinal and circumferential extent of the tumour were determined by proctoscopy and digital examination. The mobility of the tumour was assessed and classified in three categories; fully mobile, reduced mobility (tethered), or fixed. The ultrasonographic examination was then performed using a Brüel & Kjaer scanner type 1846 with a type 1850 rigid endoscopic probe, and a type 8539 transducer with a frequency of 7 mHz and a focal length of 2-5 cm, rotating in a water-filled balloon (Brüel & Kjaer, Marlborough, MA). The transducer was introduced blindly, passing the tumour if possible, and then moved distally through the tumour area with close study of the depth of tumour infiltration and of the mesorectal lymph nodes.
Interpretation of the rectal wall layers as seen on ultrasonography and the staging criteria were adapted from Hildebrand and Feifel (6, 7) (Table 1) . Irregular thinning of a layer by a hypoechoic tumour mass was interpreted as the presence of tumour invasion into the layer. Disruption of a layer by the tumour was interpreted as invasion through the layer.
Lymph node metastases were recorded if one hypoechoic lesion of more than 10 mm, or > two lesions of more than 5 mm, were detected in the mesorectum.
The examinations were performed by two surgeons who had no prior experience in ultrasonographic examinations. One surgeon performed 77 and the other 41 examinations. The TRUS findings were consecutively recorded on special forms.
Decisions concerning resectability and the need for preoperative radiotherapy were mainly based upon the endoscopic and clinical examinations. Little importance was attached to the results of TRUS because of the lack of experience with this examination. Fixed and tethered tumours were routinely given PRT. TRUS was not repeated after PRT.
After rectal resection the specimens were handled according to the standards recommended by Quirke (8). The pathologists, who were blinded as to the findings of TRUS, examined fixed specimens, and tumours were classified according to UICC TNM-categories (9). TRUS stage (uT, uN) and histopathological stage (pT, pN) were then compared.
Differences in proportions were tested with Pearson's chi square test in the Statistical Package of Social Sciences (SPSS) version 10.0 (SPSS, Chicago, Illinois).
The study was performed according to the Helsinki declaration, and approved by the Regional Ethical Research Committee.
RESULTS
TRUS examinations were successful in 97/118 (82 %) patients. In 21 patients placing of the transducer was impossible owing to tumour stenosis or high location of the tumour.
Ninety-one patients underwent rectal resection without PRT, and TRUS was successful in 81 of these patients, and they were included in the study comparing TRUS and histopathological results.
Seven patients received PRT, and 20 did not undergo rectal resection.
RESULTS OF TRUS IN PATIENTS WHO HAD RECTAL RESECTION WITHOUT PREOPERATIVE RADIOTHERAPY
Overall, T-stage was correct in 60/81 (74 %) patients, the accuracy being highest for pT2 and pT3 tumours ( Table 2) . The tumour was understaged in 11/81 (14 %) patients, and understaging was a problem in patients with advanced tumours. The tumour was overstaged in 10/81 (12 %) patients, and this was a problem in patients with low stage tumours.
TRUS correctly identified perirectal tissue invasion in 40 of 49 patients (sensitivity 85 %), and correctly predicted absence of perirectal tissue invasion in 22 (Table 3 ). There was a considerable understaging in node-positive patients; only 41 % of the patients who had lymph node metastases were identified with TRUS. The positive and negative predictive values for nodal involvement were 48 % and 72 %, respectively.
RESULTS OF TRUS IN PATIENTS WHO RECEIVED PREOPERATIVE RADIOTHERAPY
Ultrasonography was performed before application of radiotherapy, and was successful in five of seven patients (Table 4 ). In all five patients the tumour was classified as uT3. However, PRT was given since the tumours were tethered on digital examination. At subsequent histopathological examination four patients had a pT3 and one patient had a pT4 tumour. Accordingly, if the pT3 tumours were stage T3 also before irradiation, TRUS was correct in 80 % of these patients.
RESULTS OF TRUS IN 20 PATIENTS WHO DID NOT HAVE RECTAL RESECTION
In 11 patients, in whom TRUS was successfully performed, five tumours were classified as uT4, and six as uT3 (Table 5 ). Five of the latter patients had fixed (T4) tumours, whereas clinical staging was impossible in one patient with a high-level tumour. Therefore, most likely five of ten patients who had nonresectable tumours were understaged.
STAGING ACCURACY OF DIFFERENT INVESTIGATORS AND THE EFFECT OF EXPERIENCE
There was no difference between the two surgeons with respect to performing a successful examination. In patients who had rectal resection without PRT, the surgeon who performed most of the examinations obtained an overall T-stage accuracy of 46/ 58 (79 %), and the other an accuracy of 14/23 (61 %) (p = 0.09). There was no difference in the accuracy of N-staging.
The surgeon who did most of the examinations, obtained a T-stage accuracy of 75 % in the first 20 patients examined, and 82 % in the next 38 patients (p = 0.56). N-stage accuracy did not improve with more experience.
DISCUSSION
A T-stage accuracy of 75 % in the present series seems satisfactory. TRUS is examiner dependent, and these results were obtained by two surgeons without prior experience with the method. The results were also obtained without access to the most modern equipment. In comparison, the reported accuracy of T-staging in most series is around 80 %, ranging from 59 to 93 % (5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
N-staging was, however, accurate in only 65 % of the patients and the sensitivity for detection of node metastases was low. The criteria used for diagnosing node involvement by TRUS may have been too strict. Several studies have shown a sensitivity of approximately 75 %, ranging from 64 to 83 % (5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The cause of the low sensitivity is probably that the size of nodes containing metastases is often less than 5 mm (21) .
TRUS may be performed using a flexible colonoscope with an ultrasonic transducer (20) or a stiff en- dorectal probe. The latter is introduced through a proctoscope, or blindly after a proctoscopic examination, as in the present study. These investigations may be performed by radiologists, endoscopists or surgeons. In this country few radiologists and endoscopists have experience with TRUS, and the investigation is rarely performed. The present study demonstrates that surgeons can master TRUS within a reasonable time.
Recently tumour staging has become more important in the differentiated treatment of rectal cancer. In earlier reports, the incidence of local recurrence following apparently curative resection of rectal cancer often exceeded an acceptable level (22) . The routine use of adjuvant therapy was therefore recommended. On the other hand, several reports during the last 10 years have shown good results after surgery alone when the technique of mesorectal excision is applied (23) (24) (25) (26) , and the need for adjuvant therapy has been questioned. In Norway, preoperative adjuvant therapy is routinely given only to patients with fixed or tethered tumours.
The clinical usefulness of preoperative staging depends on the routines with regard to PRT. If the routines imply that most of the patients, or on the contrary, few of the patients, receive PRT, precise preoperative staging is less important. Studies performed during recent years have indicated that subgroups of patients are at high risk of local recurrence even when mesorectal excision has been applied (25, 27, 28) . Ongoing studies will probably identify the subgroups of patients who profit from adjuvant radio-and or chemotherapy (4). There may be advantages attributed to preoperative versus postoperative radiotherapy (29) . If the routines imply PRT to certain subgroups of patients, reliable preoperative staging methods are essential.
Several studies have demonstrated that patients with T3 tumours in the lower rectum have a high local recurrence rate (2, 25, 27, [30] [31] , and many argue that all these patients should be offered PRT. The present study demonstrated high predictive values of TRUS with respect to perirectal tissue invasion, in accordance with previous studies (11, 20, 32) .
However, in patients with T3 tumours, the risk of local recurrence depends on the depth of extramural tumour invasion and the distance from the tumour to the mesorectal fascia. MRI is a valuable tool in determining the relation of the tumour to the mesorectal fascia (33) (34) . Some argue that PRT should only be given to patients in whom the tumour extends to within a few mm from the mesorectal fascia. If this policy for PRT is applied, TRUS could be used as a screening method to identify patients with T3 tumours, who might then undergo further examination with MRI.
TRUS has limitations in T4-tumours because many of these patients have stenosis that precludes correct placing of the probe, and because identification of infiltration into neighbouring organs might be difficult. Other imaging techniques may be superior to TRUS in patients with advanced tumours.
TRUS with use of a stiff probe has also limitations in upper rectal cancer because placing of the probe is difficult. Colonoscopic miniprobe ultrasonography might solve the problems in staging of stenosing and high-level tumours (35) .
In the present study, TRUS had low accuracy in patients with T1 tumours. As few patients had early tumours, lack of experience may explain the results. Correct identification of these patients is essential, since they may be cured by local resection techniques.
The presence of lymph node metastases is a major independent prognostic factor, and these patients may benefit from adjuvant therapy. Planning of preoperative treatment based on N-stage might therefore be of importance. However, the sensitivity of TRUS for detection of lymph node metastases is too low, as demonstrated in the present study. Other imaging techniques also have a low sensitivity for detecting nodal involvement (5), and it seems unlikely that any reliable method will be available in the near future.
A differentiated approach to rectal cancer treatment is therefore necessary, and the timing of adjuvant therapy must be individualised. Some high risk patients will be identified based on TRUS classification of T-stage -possibly in combination with other risk factors -and may have preoperative adjuvant therapy. Some high-risk patients will not be identified until the final histopathological examination, and may then be offered postoperative adjuvant therapy.
TRUS must be evaluated and compared with other methods for preoperative staging. Digital examination is limited to the lower two-thirds of the rectum, is subjective and non-reproducible, and has an accuracy of T-stage of 40-80 % (5). In several series the accuracy of TRUS has been superior to that of computed tomography and of MRI with body coil (5). These modalities may be useful supplements in patients in whom TRUS is technically unsuccessful, and in patients with a suspected T4 tumour. As mentioned, MRI may also give information regarding the relation of the tumour to the mesorectal fascia. MRI with endorectal coil seems to have an accuracy comparable to TRUS (11), but is more expensive (15, (36) (37) (38) .
In many hospitals the preoperative staging of rectal cancer needs refinement. A question is whether the routine locoregional staging should be performed by radiologists applying MRI, or by surgeons applying TRUS. In our department, an ongoing trial comparing the two modalities will probably answer this question.
In conclusion, the present study indicates that TRUS is a valuable tool in staging of rectal cancer. Surgeons can master TRUS within a reasonable time and obtain clinical useful predictive information of T-stage, helping to identify patients who should receive adjuvant therapy or who should undergo supplementary MRI examination. The accuracy of Nstaging is, however, too low for selection of patients who should have preoperative adjuvant therapy because of lymph node metastases.
